A recent MRI analysis of the pivotal OCEANIC-STROKE trial has indicated a complete lack of association between infarct patterns and asundexian’s efficacy.
|Videos|May 30, 2017
Lurasidone for Bipolar Depression
Author(s)Lisa Neuman
Dr. Kiki Chang sits down with MD Magazine and talks about the latest data on lurasidone.
Advertisement
Kiki Chang, MD, professor of Psychiatry & Behavioral Sciences at Stanford University Medical Center, discusses the latest research on lurasidone as treatment for major depression with bipolar I disorder.
Advertisement
Related to this article
A new analysis of 4 major trials has revealed the association between lower SBP and higher TTR and the risk of recurrent stroke after intracerebral hemorrhage.
Data from the phase 2a BIRCH trial demonstrated the treatment’s improvements in mRS and NLR, positioning it for a late-phase trial in the future.
A new analysis of the BRIDGE-TNK trial has demonstrated that patients with cardioembolism are more likely to derive benefit than those with large artery atherosclerosis.
Check out highlights from news published on day 3 of CHEST 2026, spanning COPD, pulmonary embolism, pulmonary hypertension, and AI.
At CHEST 2026, Retno Ariza Soemarwoto, MD, discusses curcumin’s effect on IL-17 in COPD, bioavailability, and what a guideline-ready trial needs.
Preview 8 late-breaking studies and HCPLive's investigator interviews at ASN Kidney Week 2026, spanning IgAN, dialysis, transplantation, and CKD.
Todd Schlesinger, MD, discusses Ameluz PDT for sBCC, adjuvant cemiplimab, remibrutinib for symptomatic dermographism, and nonsurgical skin cancer care.
Advertisement
Advertisement
Trending on HCPLive
1
TTR and Systolic Blood Pressure Load Control Improve Recurrent Stroke Risk
2
Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD
3
Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD
4
ASN Kidney Week 2026 Preview: 8 Late-Breakers We’ll Unpack With the Investigators
5